NEW YORK (GenomeWeb) – Rosetta Genomics announced today that its proposed merger with Genoptix has been scuttled after it failed to secure the necessary shareholder approval.

Rosetta said that as a result, it is obligated to reimburse Genoptix $750,000 in three installments, the first of which is due March 22. It added that Genoptix has indicated that it remains interested in pursuing a business arrangement with Rosetta, although it did not provide details about any potential deal.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.